Foundational guide
Selank Benefits: Graded by Organism and Tier
This compound is a registered medicine in one country and absent from the Western evidence system entirely. Grading its benefit claims means holding both facts at once.
Selank benefits are unusual to grade, because this compound sits in two evidence systems at once. It is a registered medicine in Russia with a real clinical literature behind it, and it is absent from the Western regulatory system entirely, with no FDA, EMA or MHRA authorisation and no genuine registered Western trial.
Most writing about it picks one of those facts and drops the other. Pages selling the compound cite the registration and imply approval generally. Pages debunking it report that a search found no trials and conclude that nothing exists. Both are wrong in the same way: they treat one evidence system as though it were the whole world.
Supplier publishing lot-level data
Selank, Ascension Peptides
Every lot carries certificates from two independent laboratories. The code below halves the listed price on the vial.
The published certificate for lot 29-01260229 assays this vial at 12.29 mg against a 10 mg label, and reports no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Kovera Labs and MZ Biolabs certificates per lot
- Carriage free above $250
- Dispatched same day before 2pm CST
Supplied for laboratory research use and not for human consumption. Affiliate links: a commission may be earned at no cost to the reader, and it does not affect the assessment above. Prices verified August 21, 2026.
Two systems, one compound
The compound is a synthetic heptapeptide derived from tuftsin, an endogenous peptide, developed in Russia and studied there principally as an anxiolytic.
A national registration means a regulator reviewed a dossier covering manufacture, quality control, preclinical work and clinical data, and permitted sale for a stated indication. That is an institutional judgement about a real product, and it is a great deal more than any research chemical has behind it.
What differs between regulatory systems is how much of the underlying evidence is publicly retrievable, whether studies were registered before they began, and how much independent replication supports the conclusion. Much of the literature here is published in Russian in journals that are not comprehensively indexed in the databases most readers search, so an English search returning little says something about the search rather than about the compound.
Every claim about Selank benefits therefore needs two labels rather than one: which organism, and which evidence system. The correct posture is neither acceptance nor dismissal. It is that clinical evidence exists, that it is not available to inspect in the way a reader would normally check a claim, and that no Western trial exists to cite. No trial registry identifier should be attached to this compound at all.
Selank benefits graded by organism, tier and jurisdiction
| Claim | Strongest support | Organism | Where that evidence sits |
|---|---|---|---|
| Anxiolytic effect | Clinical use in an approved indication | Human | Russian regulatory system, not independently checkable from outside |
| Reduced situational tension | Clinical literature plus behavioural assays | Human and rodent | Russian literature; rodent assays published more broadly |
| Effects on anxiety related behaviour | Standard behavioural tests | Mouse and rat | Animal literature |
| Modulation of neurotransmitter systems | Mechanistic experiments | Rat and cell culture | Animal and in vitro literature |
| Improved attention or memory | Not established as an outcome in Western trials | Human claims, unblinded | Anecdote and secondary claims |
| Sleep improvement | Not established in any controlled Western trial | Human, uncontrolled | Anecdote |
| Immune modulation | Inference from the parent peptide's known role | Not demonstrated for this derivative as a clinical outcome | Mechanistic inference |
| Antidepressant effect | Not an approved indication and not established in Western trials | Human claims | Anecdote and extrapolation |
The distinction between rows two and five is the one that matters most. The first has an institution behind it, in one jurisdiction, for a stated indication. The second has people on the internet, and the fact that both appear on the same vendor benefit list is what makes those lists misleading rather than merely optimistic.
The mechanism claims and what they license
Mechanistic accounts in circulation attribute this peptide's effects to modulation of monoaminergic and GABAergic signalling and to interference with the degradation of endogenous peptides, with supporting work in rats and in cell culture.
Those accounts describe candidate pathways. Confirming a mechanism requires showing that the pathway is engaged, that engaging it produces the effect, and that blocking it removes the effect. Even a fully confirmed mechanism establishes only that the compound acts on that pathway, not that a person benefits, because pathways have compensatory arms and tissue specific consequences.
The asymmetry to hold on to is that mechanistic detail is cheap and outcome data is expensive. A page can describe receptor interactions in great depth without a single controlled human result standing behind any of it, and the depth of the description carries no information about whether the outcome exists.
The search trap that distorts this topic
A registry keyword search matches text anywhere in a record. Searching this compound returns a set of interventional studies, and reading their titles shows what they actually are: an antiseizure drug in epilepsy, transcranial stimulation for dyslexia, telephone delivered psychotherapy for depression, neurofeedback training, balance exercises. Not one is a study of this peptide.
This is why a count from a search result should never be quoted. It reports how many records contained a matching string somewhere, which is a fact about a text index. Both errors follow from it: a page reporting that several trials exist has misread false matches as real ones, and a page reporting a specific number of trials has quoted a number that refers to nothing.
Why an anxiolytic claim is harder to check than most
Two features of this particular outcome make the benefit question stiffer than it would be for a metabolic compound.
The first is that the outcome is a report. Anxiety is measured with rating scales completed by a participant or administered by a clinician, and both convert an experience into a number through human judgement. That is standard practice and it works inside a blinded trial, because neither the participant nor the assessor knows the allocation. Outside one, the scale measures the experience plus the expectation, and nothing separates them afterwards. Placebo response is large in anxiolytic research, large enough that trials in the field are designed around it rather than treating it as background noise.
The second is that an approved indication is narrower than a benefit list. A registration permits sale for a stated condition, assessed on stated outcomes, in a stated population. Vendor pages routinely take that approval and stretch it across attention, sleep, mood, motivation and immune function, none of which was the indication. Even taking the Russian clinical evidence at full value, it supports the thing it was assessed for and not the surrounding list, and the stretch happens quietly enough that readers rarely notice where the supported claim ended.
Both features push in the same direction. They make honest accounts and enthusiastic accounts look identical from outside, which is why the tier and the jurisdiction have to be stated with every claim rather than assumed from context.
What would move any row up a tier
For the anxiolytic claim, the missing item is not evidence in general but evidence of a particular kind: a pre registered randomised trial, blinded, with a pre specified primary outcome on a validated scale, published in full with its analysis population and dropouts stated, and then replicated by an independent group.
For the cognitive, sleep and immune claims the gap is larger, because no controlled human outcome data supports them in any jurisdiction that a reader can check. Those rows do not need replication. They need a first study.
Until then the accurate summary of Selank benefits has three parts. Real clinical use and regulatory approval in one country. A rodent and cell literature that supports mechanistic and behavioural statements about rodents and cells. And an empty Western trial tier, which is a fact about the evidence system rather than a verdict on the molecule.
Frequently asked questions
- Does Russian registration mean the compound works?
- It means a regulator reviewed a dossier and permitted sale for an indication. That is a real judgement made on real evidence. It is not equivalent to a Western registration trial, and the underlying data is generally not retrievable by a reader outside the system, so it cannot be independently checked the way a published trial can.
- Why can no trial registry number be cited?
- Because no genuine registered Western trial of this compound exists. Records that surface in a registry search are false matches, discussed below.
- Are the rodent findings evidence of benefit in people?
- They are evidence about mice and rats in specific behavioural assays. Translation from rodent anxiety models to human anxiety disorders has failed often across psychiatry, which is why those findings justify human trials rather than replacing them.
- Is the cognitive or nootropic claim supported?
- Not by controlled Western evidence. It is largely an extension of the anxiolytic claim, on the reasoning that a less anxious person performs better, which is plausible and is not the same as a demonstrated cognitive effect.
- Does the tuftsin connection support immune claims?
- The parent peptide has a documented immunological role. A derivative is a different molecule, and inheriting a property from a parent structure is an assumption that has to be tested rather than assumed.
Limitations of the evidence
The effects described here are sorted by organism and evidence tier, and a claim's tier is not a statement that it transfers to humans outside the studied setting. Where a finding comes from animal or cell work, it stays there. Selank is registered as a medicine in Russia, which means a national regulator reviewed a dossier and permitted sale for a stated indication. It holds no FDA, EMA or MHRA authorisation, no published Western registration trial exists, and no trial registry identifier can honestly be cited for it. Much of the underlying clinical literature is published in Russian in journals that are not comprehensively indexed in English language databases, so a reader outside Russia often cannot inspect the study behind a claim. Nothing here describes or recommends human use.